Вот интересные результаты исследования:
Симвастатин 20 мг раз в день плюс витамин D3 1000 международных единиц два раза в день при применении в течение 12-24 недель уменьшали в рандомизированном плацебо-контролированном исследовании частоту приступов мигрени почти в два раза.
Ссылка на новость:
Novel Drug Combination Prevents Migraine
Текст новости:
Most guideline-recommended drugs for preventing migraine are only moderately effective and have substantial side effects (Neurology 2012; 78:1337). In this study, researchers in Boston tested a novel drug combination for migraine prophylaxis — simvastatin plus vitamin D. The idea came from two observations: First, because migraine is associated with excess risk for vascular disorders, propensity to migraine might be reduced by statins, which improve endothelial function. Second, in a recent observational study, statin use was associated with lower prevalence of “severe headache or migraine” in people with higher serum vitamin D levels (Cephalalgia 2015; 35:757).
Fifty-seven adults with episodic migraine (4–14 migraine days per month) were randomized to simvastatin (20 mg twice daily) plus vitamin D3 (1000 IU twice daily) or to double placebo. During the first 3 months of treatment, the median number of migraine days decreased by 8 with active therapy and increased by 1 with placebo (P<0.001). Findings were similar during months 4 through 6. The proportions of patients with ≥50% reduction in migraine days during months 4 to 6 were 29% with active treatment and 3% with placebo treatment (P=0.03). Side effects were negligible, and blinding was successful (according to standardized methods to assess blinding).
Comment
These results — showing that a well-tolerated drug combination was reasonably effective for migraine prevention — are quite eye-catching. However, the authors themselves call for replication of their findings in a larger population.
Оригинальная статья:
Buettner C et al. Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol 2015 Dec; 78:970. (http://dx.doi.org/10.1002/ana.24534)
